GAITHERSBURG, Md., Sept. 15, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the launch of the Company's Hair Restoration Wound Care Program at the 19th Annual Scientific Meeting of the International Society of Hair Restoration Surgeons being held from September 14-18 in Anchorage, Alaska.
Cytomedix is showcasing the AutoloGel™ System at their exhibit where hair restoration surgeons can learn more about the benefits of AutoloGel PRP Gel to enhance outcomes in hair transplant surgery. In conjunction with this outreach, the Company introduced its web-based marketing initiative with the launch of www.prphairrestoration.com, a website designed to provide hair restoration specialists with the tools to integrate PRP Gel into their post-operative wound care protocols, the rationale for use and the science behind PRP for follicular unit transplant, as well as to generate new patient referrals. The site also provides a fast-growing list of surgeons offering AutoloGel PRP in their practice.
Alan J. Bauman, M.D., Board Certified hair restoration surgeon, Boca Raton, Florida, stated, "The use of AutoloGel PRP applied to hair transplant wounds has had a positive impact on the rate and quality of post-operative care. Both our experienced team and our patients are delighted with the simplicity and speed of the PRP gel technique and the visual improvement in wound recovery one day post-surgery."
"Platelets are crucial to the complete healing of wounds, whether accidental or surgical. In order for a wound to heal naturally, its environment must have the right supply of nutrients. AutoloGel PRP delivers a physiologically relevant concentration of platelets thereby stimulating the natural healing processes in the wounds at the donor and recipient sites during the transplant procedure," noted Martin P. Rosendale, Chief Executive Officer of Cytomedix. "Previous studies using AutoloGel PRP by Robert J. Reese, D.O., a Board Certified hair restoration surgeon, Edina, Minnesota, have shown improved healing with less crusting, swelling, and redness after the hair transplant procedure."
"We are excited to launch our PRP Hair Restoration Wound Care Program before an audience of the world's leading hair restoration surgeons. With over 100,000 surgical hair restoration procedures performed annually in the U.S.1, we believe this is an attractive market opportunity for us. AutoloGel is the only PRP product that is cleared by the U.S. Food and Drug Administration for wound management and Cytomedix is the only PRP exhibitor at this important scientific meeting. We expect exposure at ISHRS to drive use of AutoloGel PRP for this private pay indication," added Mr. Rosendale.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma ("PPP") and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, the likelihood of obtaining a positive reimbursement determination on the submission, the likelihood and the extent of beneficial effect of such determination on CMS costs and care, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2010, filed with the SEC and other subsequent filings. These filings are available at http://www.sec.gov.
1 ISHRS 2010 Practice Census Results